Jonathan Lim, Associate Faculty at Cancer Research UK Manchester Institute, Lead of RISE Consortium at RISE Manchester, Deputy Lead of MANIFEST Consortium at MANIFEST IO, shared on LinkedIn:
“A major milestone for MANIFEST IO.
Launching our prospective recruitment represents a significant milestone since we launched in Q4 2024. In doing so, we will have the opportunity to learn from every patient.
Through deep clinical and biological profiling, we are working to better understand:
- Why cancer immunotherapies succeed
- Why toxicities occur
- How we can deliver more precise, personalized treatment.
This is only possible because of an incredible collaboration between patients, clinicians, research teams, scientists, NHS partners, industry and funders. Thank you to everyone who has helped bring MANIFEST to this point.
Read more in The Christie NHS Foundation Trust press release
Also featured in last Sunday’s The Observer UK – featuring the story of our first participant; a powerful reminder that research is driven by patients whose generosity will benefit many others.”
You can also read: ‘Can ctDNA Predict Both Benefit and Toxicity From Immunotherapy?‘
